Loading...
•
Jun 30
Reneo Pharmaceuticals Q2 2025 Earnings Report
Reneo Pharmaceuticals reported a higher net loss in Q2 2025 as R&D and G&A expenses increased, driven by expanded clinical activity.
Key Takeaways
In Q2 2025, Reneo Pharmaceuticals experienced an increase in operating expenses due to advancing clinical trials and higher personnel costs. Despite the growing investment in R&D, the company maintains a strong cash position of $83.4 million to support operations into Q4 2026. The net loss widened to $15.4 million, or $1.14 per share.
Net loss rose to $15.4 million in Q2 2025 compared to $14.1 million in Q2 2024.
R&D expenses increased to $12.6 million, driven by clinical trial and manufacturing costs.
Cash and cash equivalents stood at $83.4 million at quarter-end.
Company expects cash runway into Q4 2026, supporting pipeline expansion efforts.
Reneo Pharmaceuticals
Reneo Pharmaceuticals
Forward Guidance
Reneo Pharmaceuticals plans to share clinical data from its PIKture-01 trial in Q4 2025 and nominate a new PI3Kα inhibitor before year-end. The company remains focused on advancing its precision oncology pipeline with sufficient funding in place.
Positive Outlook
- Monotherapy and fulvestrant combination trial arms completed enrollment.
- Two new triplet arms initiated in HR+ and HER2+ breast cancer indications.
- Expected data release for PIKture-01 trial in Q4 2025.
- Nomination of new PI3Kα inhibitor anticipated by end of 2025.
- Cash runway expected to last into Q4 2026.
Challenges Ahead
- Net loss increased YoY due to expanded R&D activities.
- G&A costs rose from higher personnel-related expenses.
- No revenue reported due to clinical-stage operations.
- Decline in total assets from prior year-end levels.
- Weighted average shares increased significantly, diluting EPS.